Greenwich Lifesciences Inc reports results for the quarter ended in March - Earnings Summary

Greenwich Lifesciences

22/05/2024 22:21

* Greenwich Lifesciences Inc  GLSI.OQ  reported a quarterly
adjusted loss of 19 cents​​ per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -16 cents.  The lone analyst forecast for the
quarter was for a loss of 20 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Greenwich Lifesciences Inc's reported EPS for the quarter
was a
loss of 19 cents​.
    * Greenwich Lifesciences Inc shares had fallen by 32.1% this
quarter and gained 28.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Greenwich
Lifesciences Inc is $36.00 
This summary was machine generated from LSEG data May 22 at
09:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.20          -0.19          Beat
 Dec. 31 2023      -0.20          -0.21          Missed
 Jun. 30 2023      -0.23          -0.13          Beat